Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Novartis 23.29% 38.56% 14.47%

Does the media prefer NVO or NVS?

In the previous week, Novo Nordisk A/S had 17 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 16 mentions for Novartis. Novartis' average media sentiment score of 0.91 beat Novo Nordisk A/S's score of 0.18 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 16 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Novartis 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AZN or NVO?

In the previous week, Astrazeneca had 25 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 58 mentions for Astrazeneca and 33 mentions for Novo Nordisk A/S. Astrazeneca's average media sentiment score of 1.03 beat Novo Nordisk A/S's score of 0.18 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 41 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 16 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.96 $15.51B $4.26 12.20 Sanofi $49.35B 2.22 $8.84B $3.58 12.63

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Sanofi 16.95% 13.39% 7.58%

Does the media favor NVO or SNY?

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Sanofi. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.69 beat Novo Nordisk A/S's score of 0.18 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 16 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Sanofi 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GSK or NVO?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.49 $7.54B $3.85 13.77 Novo Nordisk A/S $46.80B 4.96 $15.51B $4.26 12.20

Is GSK or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media prefer GSK or NVO?

In the previous week, GSK had 3 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 36 mentions for GSK and 33 mentions for Novo Nordisk A/S. GSK's average media sentiment score of 0.44 beat Novo Nordisk A/S's score of 0.18 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 11 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 16 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts prefer TAK or NVO?

Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 26.19%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Novo Nordisk A/S 2 Sell rating(s) 16 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.13

Does the media favor TAK or NVO?

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.77 beat Novo Nordisk A/S's score of 0.18 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 16 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Novo Nordisk A/S (NVO) Competitors

$51.56 +0.60 (+1.18%)

Closing price 03:59 PM Eastern

Extended Trading

$51.55 -0.01 (-0.02%)

As of 04:02 PM Eastern

Compare

NVO vs. NVS, AZN, SNY, GSK, and TAK

Should you buy Novo Nordisk A/S stock or one of its competitors? MarketBeat compares Novo Nordisk A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novo Nordisk A/S include Novartis (NVS), Astrazeneca (AZN), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Novo Nordisk A/S compare to Novartis?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Novo Nordisk A/S presently has a consensus target price of $65.56, indicating a potential upside of 26.19%. Novartis has a consensus target price of $141.20, indicating a potential downside of 10.97%. Given Novo Nordisk A/S's higher probable upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	23.29%	38.56%	14.47%

In the previous week, Novo Nordisk A/S had 17 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 16 mentions for Novartis. Novartis' average media sentiment score of 0.91 beat Novo Nordisk A/S's score of 0.18 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	16 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Novartis	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.96	$15.51B	$4.26	12.20
Novartis	$54.53B	5.55	$13.98B	$6.63	23.92

Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.4%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Astrazeneca presently has a consensus price target of $211.00, suggesting a potential upside of 21.56%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 26.19%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Astrazeneca had 25 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 58 mentions for Astrazeneca and 33 mentions for Novo Nordisk A/S. Astrazeneca's average media sentiment score of 1.03 beat Novo Nordisk A/S's score of 0.18 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	41 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	16 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novo Nordisk A/S has lower revenue, but higher earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.58	$10.23B	$6.66	26.06
Novo Nordisk A/S	$46.80B	4.96	$15.51B	$4.26	12.20

Astrazeneca has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.4%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 37.23% compared to Astrazeneca's net margin of 17.02%. Novo Nordisk A/S's return on equity of 63.31% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.95%	13.25%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Summary

Novo Nordisk A/S beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Sanofi?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Sanofi. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.69 beat Novo Nordisk A/S's score of 0.18 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	16 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sanofi	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.4%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.96	$15.51B	$4.26	12.20
Sanofi	$49.35B	2.22	$8.84B	$3.58	12.63

Novo Nordisk A/S currently has a consensus price target of $65.56, indicating a potential upside of 26.19%. Sanofi has a consensus price target of $49.50, indicating a potential upside of 9.45%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Sanofi	16.95%	13.39%	7.58%

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to GSK?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

In the previous week, GSK had 3 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 36 mentions for GSK and 33 mentions for Novo Nordisk A/S. GSK's average media sentiment score of 0.44 beat Novo Nordisk A/S's score of 0.18 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	11 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	16 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.49	$7.54B	$3.85	13.77
Novo Nordisk A/S	$46.80B	4.96	$15.51B	$4.26	12.20

GSK presently has a consensus price target of $53.00, indicating a potential upside of 0.00%. Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 26.19%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

GSK has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.4%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.4%. GSK pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novo Nordisk A/S beats GSK on 11 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.4%. Takeda Pharmaceutical pays out 123.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.01	-$1.01B	$0.39	45.59
Novo Nordisk A/S	$46.80B	4.96	$15.51B	$4.26	12.20

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novo Nordisk A/S has a net margin of 37.23% compared to Takeda Pharmaceutical's net margin of 4.31%. Novo Nordisk A/S's return on equity of 63.31% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
Novo Nordisk A/S	37.23%	63.31%	22.19%

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.77 beat Novo Nordisk A/S's score of 0.18 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	16 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 26.19%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$231.67B	$343.46B	$7.07B	$23.77B
Dividend Yield	3.52%	2.63%	2.66%	4.20%
P/E Ratio	12.18	31.38	27.43	30.92
Price / Sales	4.96	5.42	580.91	14.09
Price / Cash	10.60	14.31	49.60	31.94
Price / Book	7.90	8.61	10.14	4.83
Net Income	$15.51B	$11.61B	$3.60B	$1.07B
7 Day Performance	7.75%	3.76%	-0.99%	0.63%
1 Month Performance	7.43%	2.37%	-3.62%	0.88%
1 Year Performance	-3.74%	32.86%	20.83%	15.54%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.2352 of 5 stars	$51.56 +1.2%	$65.56 +27.2%	-26.2%	$230.22B	$46.80B	12.10	69,505	Upcoming Earnings
NVS Novartis	2.8597 of 5 stars	$154.19 +0.2%	$141.20 -8.4%	+37.6%	$293.80B	$54.53B	22.06	75,267
AZN Astrazeneca	4.478 of 5 stars	$170.17 +0.5%	$211.00 +24.0%	+20.0%	$263.53B	$60.44B	25.51	96,100	Positive News Earnings Report Short Interest Increase
SNY Sanofi	3.2821 of 5 stars	$44.10 +0.8%	$49.50 +12.2%	-8.0%	$106.74B	$47.35B	12.30	74,846	News Coverage Upcoming Earnings Gap Up
GSK GSK	2.6956 of 5 stars	$51.27 +1.0%	$53.00 +3.4%	+43.4%	$103.63B	$43.07B	13.31	66,841	Trending News Dividend Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Summary

How does Novo Nordisk A/S compare to GSK?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Novartis?

Do analysts prefer NVO or NVS?

Is NVO or NVS more profitable?

Does the media prefer NVO or NVS?

Which has better earnings & valuation, NVO or NVS?

Which has more volatility & risk, NVO or NVS?

Is NVO or NVS a better dividend stock?

Do institutionals and insiders hold more shares of NVO or NVS?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Do analysts recommend AZN or NVO?

Does the media favor AZN or NVO?

Do insiders and institutionals believe in AZN or NVO?

Which has higher valuation & earnings, AZN or NVO?

Which has more volatility & risk, AZN or NVO?

Is AZN or NVO a better dividend stock?

Is AZN or NVO more profitable?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Does the media favor NVO or SNY?

Is NVO or SNY a better dividend stock?

Which has more volatility & risk, NVO or SNY?

Which has stronger valuation and earnings, NVO or SNY?

Do analysts rate NVO or SNY?

Is NVO or SNY more profitable?

Do insiders & institutionals have more ownership in NVO or SNY?

Summary

How does Novo Nordisk A/S compare to GSK?

Does the media prefer GSK or NVO?

Do insiders and institutionals have more ownership in GSK or NVO?

Which has stronger earnings & valuation, GSK or NVO?

Do analysts prefer GSK or NVO?

Which has more volatility and risk, GSK or NVO?

Is GSK or NVO more profitable?

Is GSK or NVO a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Is TAK or NVO a better dividend stock?

Which has higher valuation & earnings, TAK or NVO?

Do insiders & institutionals have more ownership in TAK or NVO?

Is TAK or NVO more profitable?

Does the media favor TAK or NVO?

Do analysts prefer TAK or NVO?

Which has more volatility & risk, TAK or NVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools